Analisis Perlakuan Akuntansi Atas Selisih Kurs Dalam Transaksi Mata Uang Asing PT Kalbe Farma Tbk (KLBF)
Zentrum Economic, Business, Management, Accounting Research · 2026
DOI: 10.69657/0v23as42 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zentrum Economic, Business, Management, Accounting Research, 2026. Verfasst von Novia Rizki und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
This study aims to analyze foreign currency transactions carried out by PT Kalbe Farma Tbk based on applicable accounting standards. Using a quantitative descriptive approach, this study explores the application of Financial Accounting Standards Statement (PSAK) 221 and its comparison with accounting practices applied by the company. The data collection method is carried out through analysis of the annual report and notes to the consolidated financial statements of PT Kalbe Farma Tbk in 2023. The results of the study indicate that although the company has implemented PSAK 221 in recognizing and measuring exchange rate differences, there are differences in the practices adopted, especially in determining the exchange rate used to record transactions.
Zitieren
APA
Rizki, N., Elwathan, S., Hamdayani, P., & Ramdhan, S. (2026). Analisis Perlakuan Akuntansi Atas Selisih Kurs Dalam Transaksi Mata Uang Asing PT Kalbe Farma Tbk (KLBF). Zentrum Economic, Business, Management, Accounting Research. https://doi.org/10.69657/0v23as42
Vancouver
Rizki N, Elwathan S, Hamdayani P, Ramdhan S. Analisis Perlakuan Akuntansi Atas Selisih Kurs Dalam Transaksi Mata Uang Asing PT Kalbe Farma Tbk (KLBF). Zentrum Economic, Business, Management, Accounting Research. 2026. doi:10.69657/0v23as42
BibTeX
@article{Rizki2026,
author = {Rizki, Novia and Elwathan, Syahrama and Hamdayani, Peri and Ramdhan, Syahrul},
title = {Analisis Perlakuan Akuntansi Atas Selisih Kurs Dalam Transaksi Mata Uang Asing PT Kalbe Farma Tbk (KLBF)},
journal = {Zentrum Economic, Business, Management, Accounting Research},
year = {2026},
doi = {10.69657/0v23as42}
}
EUVIMED